FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382777588> ?p ?o ?g. }

• W4382777588 endingPage "1528" @default.
• W4382777588 startingPage "1520" @default.
• W4382777588 abstract "The randomized phase II VELO trial showed that the addition of panitumumab to trifluridine/tipiracil significantly improves progression-free survival (PFS) as compared to trifluridine/tipiracil in third-line therapy in patients with refractory RAS wild-type (WT) metastatic colorectal cancer (mCRC). With longer follow-up, final overall survival results and posttreatment subgroup analysis are presented. Sixty-two patients with refractory RAS WT mCRC were randomly assigned to receive, as third-line therapy, trifluridine/tipiracil alone (arm A) or in combination with panitumumab (arm B). Primary endpoint was PFS; secondary endpoints included overall survival (OS) and overall response rate (ORR). Median OS was 13.1 months (95% CI 9.5-16.7) in arm A compared to 11.6 months (95% CI 6.3-17.0) in arm B (HR: 0.96, 95% CI 0.54-1.71, P = .9). To evaluate the impact of subsequent lines of treatment, subgroup analysis was performed for the 24/30 patients in arm A, that received fourth-line therapy after disease progression. Median PFS was 4.1 months (95% CI 1.44-6.83) for 17 patients treated with anti-EGFR rechallenge as compared to 3.0 months (95% CI 1.61-4.31) for seven patients that received other therapies (HR: 0.29, 95% CI 0.10-0.85, P = .024). Median OS from the start of fourth-line treatment was 13.6 months (95% CI 7.2-20), and 5.1 months (95% CI 1.8-8.3) for patients treated with anti-EGFR rechallenge vs other therapies, respectively (HR: 0.30, 95% CI 0.11-0.81, P = .019). Final results of the VELO trial support the role of anti-EGFR rechallenge in the continuum of care of patients with RAS/BRAF WT mCRC." @default.
• W4382777588 created "2023-07-02" @default.
• W4382777588 creator A5001896992 @default.
• W4382777588 creator A5002124283 @default.
• W4382777588 creator A5004016643 @default.
• W4382777588 creator A5006208754 @default.
• W4382777588 creator A5007575010 @default.
• W4382777588 creator A5008674075 @default.
• W4382777588 creator A5009130863 @default.
• W4382777588 creator A5011947444 @default.
• W4382777588 creator A5020435379 @default.
• W4382777588 creator A5020655022 @default.
• W4382777588 creator A5032164411 @default.
• W4382777588 creator A5037047992 @default.
• W4382777588 creator A5038665049 @default.
• W4382777588 creator A5039682482 @default.
• W4382777588 creator A5043177546 @default.
• W4382777588 creator A5047539709 @default.
• W4382777588 creator A5062813302 @default.
• W4382777588 creator A5076690603 @default.
• W4382777588 creator A5083277135 @default.
• W4382777588 creator A5085124809 @default.
• W4382777588 creator A5088304855 @default.
• W4382777588 creator A5092126373 @default.
• W4382777588 date "2023-06-30" @default.
• W4382777588 modified "2023-09-26" @default.
• W4382777588 title "Panitumumab plus trifluridine/tipiracil as anti‐<scp>EGFR</scp> rechallenge therapy in patients with refractory <scp><i>RAS</i></scp> wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase <scp>II VELO</scp> trial" @default.
• W4382777588 cites W2062109911 @default.
• W4382777588 cites W2156834559 @default.
• W4382777588 cites W242040007 @default.
• W4382777588 cites W2615601352 @default.
• W4382777588 cites W2901178367 @default.
• W4382777588 cites W2901367407 @default.
• W4382777588 cites W2979386314 @default.
• W4382777588 cites W2999771324 @default.
• W4382777588 cites W3153189337 @default.
• W4382777588 cites W3182019035 @default.
• W4382777588 cites W3191292273 @default.
• W4382777588 cites W4224880107 @default.
• W4382777588 cites W4283587297 @default.
• W4382777588 cites W4307401860 @default.
• W4382777588 cites W4320495940 @default.
• W4382777588 cites W4362584062 @default.
• W4382777588 cites W4377011318 @default.
• W4382777588 doi "https://doi.org/10.1002/ijc.34632" @default.
• W4382777588 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37391938" @default.
• W4382777588 hasPublicationYear "2023" @default.
• W4382777588 type Work @default.
• W4382777588 citedByCount "0" @default.
• W4382777588 crossrefType "journal-article" @default.
• W4382777588 hasAuthorship W4382777588A5001896992 @default.
• W4382777588 hasAuthorship W4382777588A5002124283 @default.
• W4382777588 hasAuthorship W4382777588A5004016643 @default.
• W4382777588 hasAuthorship W4382777588A5006208754 @default.
• W4382777588 hasAuthorship W4382777588A5007575010 @default.
• W4382777588 hasAuthorship W4382777588A5008674075 @default.
• W4382777588 hasAuthorship W4382777588A5009130863 @default.
• W4382777588 hasAuthorship W4382777588A5011947444 @default.
• W4382777588 hasAuthorship W4382777588A5020435379 @default.
• W4382777588 hasAuthorship W4382777588A5020655022 @default.
• W4382777588 hasAuthorship W4382777588A5032164411 @default.
• W4382777588 hasAuthorship W4382777588A5037047992 @default.
• W4382777588 hasAuthorship W4382777588A5038665049 @default.
• W4382777588 hasAuthorship W4382777588A5039682482 @default.
• W4382777588 hasAuthorship W4382777588A5043177546 @default.
• W4382777588 hasAuthorship W4382777588A5047539709 @default.
• W4382777588 hasAuthorship W4382777588A5062813302 @default.
• W4382777588 hasAuthorship W4382777588A5076690603 @default.
• W4382777588 hasAuthorship W4382777588A5083277135 @default.
• W4382777588 hasAuthorship W4382777588A5085124809 @default.
• W4382777588 hasAuthorship W4382777588A5088304855 @default.
• W4382777588 hasAuthorship W4382777588A5092126373 @default.
• W4382777588 hasBestOaLocation W43827775881 @default.
• W4382777588 hasConcept C121608353 @default.
• W4382777588 hasConcept C126322002 @default.
• W4382777588 hasConcept C141071460 @default.
• W4382777588 hasConcept C142424586 @default.
• W4382777588 hasConcept C143998085 @default.
• W4382777588 hasConcept C187960798 @default.
• W4382777588 hasConcept C203092338 @default.
• W4382777588 hasConcept C2776694085 @default.
• W4382777588 hasConcept C2778332735 @default.
• W4382777588 hasConcept C2780739268 @default.
• W4382777588 hasConcept C2781187634 @default.
• W4382777588 hasConcept C31760486 @default.
• W4382777588 hasConcept C44249647 @default.
• W4382777588 hasConcept C526805850 @default.
• W4382777588 hasConcept C535046627 @default.
• W4382777588 hasConcept C71924100 @default.
• W4382777588 hasConcept C86803240 @default.
• W4382777588 hasConcept C87355193 @default.
• W4382777588 hasConcept C90924648 @default.
• W4382777588 hasConceptScore W4382777588C121608353 @default.
• W4382777588 hasConceptScore W4382777588C126322002 @default.
• W4382777588 hasConceptScore W4382777588C141071460 @default.
• W4382777588 hasConceptScore W4382777588C142424586 @default.
• W4382777588 hasConceptScore W4382777588C143998085 @default.
• W4382777588 hasConceptScore W4382777588C187960798 @default.

• next